IP Library › Granted Patent US 11,292,846
Granted Patent B2
US 11,292,846 · App. 16/760,704 · Granted Apr 5, 2022

Bispecific antibodies binding ALK-1 and BMPR-2

Inventors: Ernst Weber (Langenfeld, DE); Joerg Meding (Wuppertal, DE); Florian Sohler (Essen, DE); Julian Marius Glueck (Essen, DE)
Assignee: Bayer Aktiengesellschaft
C07K16/2863G01N33/6854C07K2317/31C07K2317/622C07K2317/75C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,292,846
App. No.
16/760,704
Granted
Apr 5, 2022
Kind
B2
Abstract

Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.

Claims (2)

1. A bispecific antibody (BsAB), wherein said BsAB comprises an ALK-1 binding domain and a BMPR-2 binding domain, wherein said BsAB promotes dimerization of ALK-1 and BMPR-2, and wherein said BsAB is TPP-14696 comprising the amino acid sequences of SEQ ID NOS: 1, 8, 15, and 22 or TPP-14719 comprising the amino acid sequences of SEQ ID NOS: 29, 36, 43, and 50.

2. A BsAB according to claim 1 , wherein the ALK-1 is human ALK-1 or a fragment thereof, and wherein the BMPR-2 is human BMPR-2 or a fragment thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2020
From: MEDING, JORG; SOHLER, FLORIAN; WEBER, ERNST; GLUCK, JULIAN MARIUS
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 054067/0442 →
Priority Claims (2)
EP 17199746 · Nov 2, 2017 · regional
EP 17200666 · Nov 8, 2017 · regional
Continuity (1)
Related Publication 20200332013A1 · Oct 22, 2020
Cited By (2)
US 12,473,367 US 12,686,720